Search research articles
Contact Us
Filters
Showing results (101-110 of 199) with videos related to
Page
of 20
Sort By:
Targeted Oncology
|
May 3, 2021
Savolitinib ± Osimertinib in Japanese Patients with Advanced Solid Malignancies or EGFRm NSCLC: Ph1b TATTON Part C
Kiyotaka Yoh, Tomonori Hirashima, Hideo Saka, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 2, 2022
Biology and Targetability of the Extended Spectrum of PIK3CA Mutations Detected in Breast Carcinoma
Hope S Rugo, Kira Raskina, Alexa B Schrock, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 17, 2014
Noninvasive detection of response and resistance in EGFR-mutant lung cancer using quantitative next-generation genotyping of cell-free plasma DNA
Geoffrey R Oxnard, Cloud P Paweletz, Yanan Kuang, et al.
JCO Precision Oncology
|
September 3, 2021
Characterization of Non-Small-Cell Lung Cancers With MET Exon 14 Skipping Alterations Detected in Tissue or Liquid: Clinicogenomics and Real-World Treatment Patterns
Jessica K Lee, Russell Madison, Anthony Classon, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 10, 2021
The Pan-Tumor Landscape of Targetable Kinase Fusions in Circulating Tumor DNA
Jessica K Lee, Mehlika Hazar-Rethinam, Brennan Decker, et al.
The Oncologist
|
June 9, 2020
State of the Science and Future Directions for Liquid Biopsies in Drug Development
Preeti Narayan, Soma Ghosh, Reena Philip, et al.
The Oncologist
|
February 24, 2024
Real-World Clinical Performance of a DNA-Based Comprehensive Genomic Profiling Assay for Detecting Targetable Fusions in Nonsquamous NSCLC
Philip C Mack, Rachel B Keller-Evans, Gerald Li, et al.
Journal for Immunotherapy of Cancer
|
January 17, 2023
Durable responders in advanced NSCLC with elevated TMB and treated with 1L immune checkpoint inhibitor: a real-world outcomes analysis
Richard S P Huang, David P Carbone, Gerald Li, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
August 5, 2019
EGFR-Mutated Lung Cancers Resistant to Osimertinib through EGFR C797S Respond to First-Generation Reversible EGFR Inhibitors but Eventually Acquire EGFR T790M/C797S in Preclinical Models and Clinical Samples
Deepa Rangachari, Ciric To, Jason E Shpilsky, et al.
Journal for Immunotherapy of Cancer
|
November 30, 2023
Evaluation of tissue- and plasma-derived tumor mutational burden (TMB) and genomic alterations of interest in CheckMate 848, a study of nivolumab combined with ipilimumab and nivolumab alone in patients with advanced or metastatic solid tumors with high TMB
Jie He, Natallia Kalinava, Parul Doshi, et al.
Page
of 20
Search research articles
Search
Showing results (101-110 of 199) with videos related to
Sort By:
Page
of 20
Targeted Oncology
|
May 3, 2021
Savolitinib ± Osimertinib in Japanese Patients with Advanced Solid Malignancies or EGFRm NSCLC: Ph1b TATTON Part C
Kiyotaka Yoh, Tomonori Hirashima, Hideo Saka, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 2, 2022
Biology and Targetability of the Extended Spectrum of PIK3CA Mutations Detected in Breast Carcinoma
Hope S Rugo, Kira Raskina, Alexa B Schrock, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 17, 2014
Noninvasive detection of response and resistance in EGFR-mutant lung cancer using quantitative next-generation genotyping of cell-free plasma DNA
Geoffrey R Oxnard, Cloud P Paweletz, Yanan Kuang, et al.
JCO Precision Oncology
|
September 3, 2021
Characterization of Non-Small-Cell Lung Cancers With MET Exon 14 Skipping Alterations Detected in Tissue or Liquid: Clinicogenomics and Real-World Treatment Patterns
Jessica K Lee, Russell Madison, Anthony Classon, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 10, 2021
The Pan-Tumor Landscape of Targetable Kinase Fusions in Circulating Tumor DNA
Jessica K Lee, Mehlika Hazar-Rethinam, Brennan Decker, et al.
The Oncologist
|
June 9, 2020
State of the Science and Future Directions for Liquid Biopsies in Drug Development
Preeti Narayan, Soma Ghosh, Reena Philip, et al.
The Oncologist
|
February 24, 2024
Real-World Clinical Performance of a DNA-Based Comprehensive Genomic Profiling Assay for Detecting Targetable Fusions in Nonsquamous NSCLC
Philip C Mack, Rachel B Keller-Evans, Gerald Li, et al.
Journal for Immunotherapy of Cancer
|
January 17, 2023
Durable responders in advanced NSCLC with elevated TMB and treated with 1L immune checkpoint inhibitor: a real-world outcomes analysis
Richard S P Huang, David P Carbone, Gerald Li, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
August 5, 2019
EGFR-Mutated Lung Cancers Resistant to Osimertinib through EGFR C797S Respond to First-Generation Reversible EGFR Inhibitors but Eventually Acquire EGFR T790M/C797S in Preclinical Models and Clinical Samples
Deepa Rangachari, Ciric To, Jason E Shpilsky, et al.
Journal for Immunotherapy of Cancer
|
November 30, 2023
Evaluation of tissue- and plasma-derived tumor mutational burden (TMB) and genomic alterations of interest in CheckMate 848, a study of nivolumab combined with ipilimumab and nivolumab alone in patients with advanced or metastatic solid tumors with high TMB
Jie He, Natallia Kalinava, Parul Doshi, et al.
Page
of 20